Functionally perturbing oncostatin M-oncostatin M receptor signalling, a proposed MIDAS target, in TRACERx melanoma-patient-derived explants yielded reduced dysfunctional CD8<sup>+</sup> T cells, which associate with immunotherapy response, and reduced CCL4 levels. This evidence concerns the gene CD8A and melanoma.